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Highlights 
 
- An efficient CVB1 vaccine production and purification process was developed. 
- Formalin inactivation caused a dramatic change in CVB1 integrity. 
- Tween80 detergent increased CVB1 yield and stability significantly. 
- CVB1 vaccine was immunogenic and protected mice against CVB1 infection. 
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ABSTRACT 19 
 20 
Coxsackie B viruses are among the most common enteroviruses, causing a wide range of diseases. 21 
Recent studies have also suggested that they may contribute to the development of type 1 diabetes. 22 
Vaccination would provide an effective way to prevent CVB infections, and the objective of this study 23 
was to develop an efficient vaccine production protocol for the production of novel CVB vaccines. 24 
Various steps in the production of a formalin-inactivated Coxsackievirus B1 (CVB1) vaccine were 25 
optimized including the Multiplicity Of Infection (MOI) used for virus amplification, virus cultivation 26 
time, type of cell growth medium, virus purification method and formulation of the purified virus. 27 
Safety and immunogenicity of the formalin inactivated CVB1 vaccine was characterized in a mouse 28 
model. Two of the developed methods were found to be optimal for virus purification: the first 29 
employed PEG-precipitation followed by gelatin-chromatography and sucrose cushion pelleting 30 
(three-step protocol), yielding 19 fold increase in virus concentration (0.06 µg/cm2). The second 31 
method utilized tandem sucrose pelleting without a PEG precipitation step, yielding 83 fold increase 32 
in virus concentration (0.24 µg/cm2), but it was more labor-intensive and cannot be efficiently scaled 33 
up. Both protocols provide radically higher virus yields compared with traditional virus purification 34 
protocols involving PEG-precipitation and sucrose gradient ultracentrifugation. Formalin inactivation 35 
of CVB1 produced a vaccine that induced a strong, virus-neutralizing antibody response in 36 
vaccinated mice, which protected against challenge with CVB1 virus. Altogether, these results 37 
provide valuable information for the development of new enterovirus vaccines.  38 
 39 
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1. Introduction 42 
 43 
Coxsackievirus B1 (CVB1) belongs to the enterovirus (EV) family and has a non-enveloped, 44 
icosahedral ~30 nm diameter capsid, consisting of 60 copies of the structural proteins VP1-4. During 45 
replication, the viral polyprotein P1 is cleaved into structural proteins VP0, VP1 and VP3. VP0 is 46 
further processed into VP2 and VP4 in a viral RNA-driven autocatalysis reaction resulting in the 47 
formation of mature viral capsids [1-3]. 48 
EVs are the most common infection causing viruses in humans. Generally EVs infect the respiratory 49 
and gastrointestinal tracts and frequently lead to viremia. Sometimes, this can result in secondary 50 
infections in organs, such as the heart or central nervous system causing for example polio, 51 
meningoencephalitis [4-7], sepsis [8], pancreatitis [9] or myocarditis [10]. Children younger than three 52 
years are the most susceptible to severe EV diseases and recent CVB1 epidemics have caused life-53 
threatening infections in neonates [10-15]. 54 
Associations between EV infections and the development of chronic diseases such as type 1 55 
diabetes (T1D), dilating cardiomyopathy, asthma and allergies [16] have been documented. T1D is 56 
thought to result from an immune-mediated destruction of the insulin-producing ȕ-cells in the 57 
pancreas. Environmental triggers of T1D have been purported including CVBs (CVB1-6), and 58 
particularly CVB1 [17,18]. However, the mechanisms through which EVs may cause different 59 
disease pathogenesis are poorly understood, but persistent infections and viral proteases have been 60 
implicated [19-21]. 61 
Alongside traditional poliovirus vaccines, EV vaccines have been developed against a limited 62 
number of non-polio EV diseases. Three formalin-inactivated EV71 vaccines have been tested in 63 
phase 3 trials and are effective against hand-foot-and-mouth disease in children. Moreover two of 64 
them, have recently received regulatory approval in China [22].  65 
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In the present study, we describe an optimized and scalable production and purification protocol for 66 
CVB1 vaccine and demonstrate its ability to induce a strong, virus-neutralizing antibody response 67 
and protection against CVB1 infection in mice. 68 
 69 
2. Materials and Methods 70 
 71 
Virus strain, cell lines and cell culture media  72 
 73 
A field isolate CVB1 was used [17], hereinafter referred to as CVB1 and the ATCC CVB6 strain 74 
Schmitt was employed (henceforth CVB6).  CVB1 and CVB6 were propagated in green monkey 75 
kidney cells (Vero) in multilayer (Falcon Cell culture Multi-Flask or Corning hyperflask M cell culture 76 
vessel) flasks using SFM4MegaVir protein-free medium (HyClone) without fetal bovine serum (FBS). 77 
Vero-cells were cultivated in DMEM containing 10% FBS, 2 mM L-Glutamine and 1% penicillin-78 
streptomycin. Cell culture reagents were from Thermo Fisher Scientific. 79 
 80 
Optimization of CVB1 production and purification  81 
 82 
Different conditions were used for virus production and batches were designated CVB1#1-4 and 83 
CVB6#1. The details of the virus production (Supplementary Table 1.) and purification 84 
(Supplementary Table 2.) protocols are described in the supplementary material. 85 
 86 
 87 
 88 
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Virus characterization 89 
 90 
Purified viruses were run on mini-protean TGX stain-free precast gradient gels (4-20%) (BioRad). 91 
Tryptophan-containing proteins were detected in SDS-PAGE gels by UV-induced fluorescence. 92 
Subsequently, viruses were electroblotted onto a PVDF membrane and analyzed by Western blotting 93 
using mouse anti-enterovirus clone 5-D8/1 (DAKO, Glostrup, Denmark; 1:3000) for CVB1 and in-94 
house produced rat polyclonal antibody clone 1685 for CVB6, followed by incubation with IRDye-95 
labeled secondary antibodies (1:5000). Virus and impurities were assessed by densitometry analysis 96 
of SDS-PAGE gels using ImageJ software [23]. Fibronectin was also detected by Western Blotting 97 
using anti-fibronectin antibody (Sigma). Total protein concentrations of the viruses were determined 98 
using the Pierce BCA Protein Assay kit (Thermo Fischer Scientific). Vero cell residual DNA 99 
quantitation from the purified viruses was performed using the resDNASEQ quantitative qPCR kit 100 
(Applied Biosystems), Applied Biosystems 7500 Real-Time PCR system and 7500 system SDS 101 
software. 102 
Dynamic light scattering (DLS) analysis was performed with a Zetasizer Nano ZS instrument 103 
(Malvern Instruments Ltd.). The hydrodynamic diameter was determined using viruses diluted 1:10 104 
and three 10 x 10-second datasets at 25 °C. Transmission electron microscopy (TEM) analysis was 105 
performed as described [24]. Virus titers were determined in Green Monkey Kidney (GMK) cells 106 
using either TCID50 or plaque titration assays [17]. 107 
 108 
Vaccine preparation 109 
 110 
R-buffer in batch CVB1#2 was exchanged by dialysis to PBS-0.5 mM MgCl2. Virus was inactivated 111 
in 0.01% (vol/vol) formalin for 12 days at 37°C and inactivation confirmed by the lack of infective 112 
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virus in plaque titration assay. Inactivated CVB1 was diluted in PBS-0.5 mM MgCl2-0.01% formalin 113 
and stored at -70°C. 114 
 115 
Vaccinations, virus challenge, virus titering and seroneutralization assays 116 
 117 
NOD (Non-obese diabetic) mice [25] were bred and housed in a pathogen free environment at 118 
Karolinska Institutet (Stockholm, Sweden). Experiments were approved by the local ethics 119 
committee and conducted in accordance with the NIH Principles of Laboratory Animal Care and 120 
national laws. An extended monitoring of animal health was conducted regularly. Vaccinations were 121 
given interscapularly in 150 µl to NOD mice, starting at 4-6 weeks of age. In experiment 1, mice 122 
received 1.8 µg vaccine protein per injection on days 0, 21 and 35 and control mice received vaccine 123 
buffer alone. Serum was collected on days 0, 21, 35, 42 and 49 by tail bleeding or terminal heart 124 
puncture (day 49) and neutralizing antibodies against CVB1 were detected as described [26]. Mice 125 
in experiment 2 received either 1 µg or 10 µg CVB1 vaccine on days 0, 14 (both) and 28 (1 µg only) 126 
and were challenged with 106 PFU CVB1 10796 [27] by intraperitoneal injection on day 35 (un-127 
vaccinated littermates controls were also challenged). Serum samples were collected as before on 128 
days 0, 14 and 28 for the measurement of neutralizing antibody titers. Blood and pancreas were 129 
collected on days 38 and 40 respectively for the measurement of virus by standard plaque assay 130 
and the detection of viral VP1 protein by immunohistochemistry [28]. Statistical significance was 131 
determined by one-way ANOVA using GraphPad Prism version 5. 132 
 133 
 134 
 135 
 136 
 137 
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3. Results 138 
 139 
Effect of cultivation conditions on virus yields 140 
 141 
The Vero cell-line was chosen as a preferred CVB1 production host, since it is widely accepted by 142 
regulatory authorities and has been used in poliovirus vaccine production for over 30 years [29]. In 143 
order to prepare CVB1 vaccine free of animal derived contaminants, SFM4MegaVir (Hyclone) cell 144 
culture medium optimized for virus amplification was chosen. The effect of MOI and culture time on 145 
CVB1 production in Vero-cells was examined (Supplementary Figure 1). Virus yields did not differ 146 
significantly between time points with MOI 0.01 and therefore, MOI 0.01 and a cultivation time of 7 147 
DPI were selected as preferred cultivation conditions (longer incubation times guarantee strong 148 
cytopathic effect and cell detachment). 149 
 150 
Optimization of CVB1 purification 151 
 152 
We compared five different purification protocols (outlined in Figure 1). Analysis of purified virus by 153 
SDS-page showed CVB1#1 and CVB1#2 had a high purity (~99% and ~90% respectively) and 154 
highlighted the presence of proteins approximately 31, 29 and 26 kDa in size (Figure 2A) which 155 
correspond to the molecular weights of the capsid proteins VP1-3. VP1 was also recognized by 156 
Western Blotting (Figure 2B). When virus cultivation time was increased to seven days, the purity 157 
decreased (CVB1#3a was ~66% pure, as estimated by densitometry) compared to CVB1#2 (2 day 158 
cultivation). Mass spectrometry analysis identified 260 kDa band to represent fibronectin-1 (Figure 159 
2A), which was found to be the most prevalent contaminant in CVB1#3a (derived from Vero cells, 160 
data not shown). The Vero cell residual DNA quantity of the purified viruses was analyzed by qPCR. 161 
The DNA content was found to be very low and it varied between 0.0005 – 0.54 ng/µl in the finally 162 
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formulated virus or vaccine preparations (Supplementary Table 3). In the vaccine used in our 163 
experiments the amount of residual host DNA was 1 ng/dose, which is under the limit (10 ng/dose) 164 
for human parenteral vaccines given by WHO [30].  165 
The tandem pelleting protocol used for CVB1#2 and CVB1#3a (Figure 1) is quite laborious, as the 166 
initial virus concentration step also used ultracentrifugation. To streamline the protocol for CVB1#3b, 167 
we utilized a combination of PEG precipitation and 30/50% sucrose cushion pelleting (Figure 1: two-168 
step protocol). However, SDS-page  and western blotting analyses identified fibronectin as the most 169 
prominent protein purified in CVB1#3b (Figure 2A) with the virus purity estimated to be ~35% by 170 
densitometry analysis. Virus recovery from CVB1#3a was 7X higher compared with the otherwise 171 
identical batch CVB1#3b, indicating a loss of virus in the PEG-precipitation step. Nevertheless, PEG-172 
precipitation is a simple and easily scalable method for concentrating virus and also acts as a 173 
purification step. Since CVB1#3b appeared to be otherwise free of contaminants except for 174 
fibronectin, we used gelatin affinity chromatography to remove fibronectin [31]. CVB1#4, was PEG-175 
precipitated, incubated with gelatin resin and pelleted by 30/50% sucrose cushion ultracentrifugation 176 
(Figure 1: three-step protocol) and resulted in ~95% pure virus (Figure 2A). In order to demonstrate 177 
that this aforementioned three-step protocol is applicable for the purification of other enteroviruses, 178 
we also used this protocol for CVB6 purification and the result was in line with CVB1 (Figure 2C and 179 
D). 180 
The highest virus yield and infectivity titer was found in CVB1#3a (tandem pelleting protocol in the 181 
presence of 0.1% Tween80; Figure 2E), with the yield being 83 times higher than the CVB1#1 yield 182 
(purified with the conventional enterovirus purification method). Virus yields for CVB1#1-4 were 3, 183 
26, 241, 35 and 56 ng/cm2 (cultivation area) respectively, whereas their infectivity titers were 8.5 x 184 
105, 1.6 x 106, 9.8 x 106, 6.7 x 105 and 1.1 x 106 TCID50 units/cm2. CVB6 had a virus yield of 124 185 
ng/cm2 and infectivity titer 4.1 x 105 TCID50 units/cm2. Therefore, both concentration and titer 186 
measurements indicated that PEG precipitation results in substantial virus loss (Figure 2E). 187 
The quality of the purified CVB1#1–4 and CVB6#1 was determined with DLS (Figure 2F), and 188 
average sizes of the virus particles were 32 – 45 nm (Figure 2G). Due to the low concentration of 189 
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CVB1#1, the major DLS peak represents Tween micelles with size of 10 nm. In summary, DLS 190 
analysis showed all of the batches contained intact virus particles. 191 
 192 
Effect of buffers on the stability and homogeneity of the virus 193 
 194 
To enable optimal CVB1 purification, we evaluated the effect of buffer composition on virus stability 195 
and homogeneity. An important indicator of virus stability is particle size, as viruses may aggregate 196 
or dissociate into subunits during storage which can be monitored by changes in particle size by 197 
DLS. CVB1 particle size was studied in four buffers; R-buffer (pH 7.5) and citrate buffer (pH 5) are 198 
used in chromatographic purification techniques, whereas PBS-Tween (pH 7.4) and M199-Tween 199 
(pH 7.4) are suitable for vaccination. Virus stored at 4°C was measured by DLS on days 0 and 7 200 
(Figure 3). In R-buffer, the particle diameter size (37.5/34.4 nm on days 0/7) and sample 201 
polydispersity index (PdI; 0.431/0.476 days 0/7 respectively) remained constant (Figure 3A). CVB1 202 
virus showed a wider particle size range in citrate buffer (32.9/52.6 nm), but the sample was relatively 203 
monodisperse (PdI: 0.256/0.221; Figure 3B), indicating that it might aggregate during storage in 204 
acidic buffer with a low osmolality. The CVB1 batch solubilized in PBS-0.1% Tween was very 205 
homogenous (PdI: 0.234/0.230) and contained a 100% population of particles sized 46.6 nm and 206 
54.7 nm on days 0 and 7 respectively (Figure 3C). M199-0.1% Tween solubilized CVB1 was also 207 
very homogenous (PdI: 0.347/0.247) containing only particles with size 41.6 nm (d 0) and 40.0 nm 208 
(d 7; Figure 3D). The results highlight the suitability of M199 buffer, which is widely used in poliovirus 209 
vaccines, for formulating and storing CVB1 viruses as well. 210 
 211 
 212 
 213 
 214 
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Vaccine preparation and characterization 215 
 216 
We next tested the immunogenicity of the purified virus preparations. CVB1#2 was completely 217 
inactivated with formalin to produce vaccine [32] (virus titers dropped from 1.2 x 1010 PFU/ml to 0 218 
PFU/ml). However, formalin inactivation affected the virus structure and concentration. The light 219 
scattering intensity decreased 4.6X after formalin inactivation indicating a decrease in concentration. 220 
Light scattering intensity analysis showed that before the inactivation step, the derived count rate of 221 
the CVB1#2 was 7969 kcps and after the inactivation step, the scattering intensity had decreased to 222 
1713 kcps and therefore 78.5% of the virus had dispersed during the inactivation step (Figure 4A). 223 
Also, according to the SDS-PAGE and VP1-protein quantification by Western blot, the virus 224 
concentration dropped from 0.317 mg/ml before inactivation to 0.0165 mg/ml (5% recovered) after 225 
inactivation (Figure 4B). TEM analysis revealed a dramatic change in the morphology of the 226 
inactivated vaccine. Most of the virus was intact before inactivation, showing icosahedral full (white) 227 
and empty (grey) particles (Figure 4C) whereas after inactivation, the preparation had a 228 
heterogeneous and blurred appearance and only rarely were intact particles detected (Figure 4D).  229 
 230 
CVB1 vaccine is immunogenic and protects mice against CVB1 infection 231 
 232 
The immunogenicity of the CVB1 vaccine was tested in mice by injecting 3 x 1.8 µg non-adjuvanted 233 
vaccine to two mice. Sera from CVB1 immunized mice was evaluated for CVB1 neutralizing ability 234 
in vitro. Both vaccinated mice generated neutralizing antibodies at day 21 (after 1 vaccination) with 235 
titer 64 and at day 35 (after two vaccinations) the neutralizing titer was 1024 (Table 1). 236 
In the second vaccination experiment, mice received either 3 x 1 µg or 2 x 10 µg non-adjuvanted 237 
vaccine which had no adverse effects on weight gain (Figure 5A) in either group. Mice receiving 10 238 
µg vaccine showed some signs of inflammation around the injection site, hence only 2 vaccinations 239 
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were performed. All vaccinated mice mounted a strong neutralizing antibody response compared to 240 
controls (p<0.001) and similar to those seen in the first experiment (Figure 5B). On day 35, the 241 
vaccinated animals and littermate controls were challenged with 106 PFU CVB1 to examine the 242 
protective efficacy of the vaccine against infection. All mice challenged with CVB1 showed weight 243 
loss after CVB1 infection (Figure 5C). Three out of four control mice had viraemia on day 3 post 244 
infection whereas no replicating virus was detected in the blood of the vaccinated animals (0/7; 245 
Figure 5D; p<0.05). Furthermore, replicating virus was also measured in the pancreas of 3/4 control 246 
mice on day 5 post infection but in none of the vaccinated mice (Figure 5E). This was also confirmed 247 
by immunohistochemical analysis with VP1 positivity seen in the pancreas of 3/4 control mice but 248 
none of the vaccinated animals (representative images Figure 5F). These results indicate the 249 
vaccine protected against acute CVB1 infections in NOD mice.  250 
 251 
4. Discussion 252 
 253 
For the production of new vaccines, the physicochemical and immunological properties of a virus 254 
need to be carefully characterized and standardized. In the enterovirus vaccine field, the production, 255 
purification, formulation and analysis protocols have been standardized for polioviruses [33,34]. 256 
However, very limited information is available regarding the effect of formalin-inactivation on the 257 
quality and morphology of enterovirus particles despite the fact this is the method of choice for 258 
inactivating and introducing new enterovirus vaccines (including EV71 vaccines [35]) to the market. 259 
In this study, our objective was to develop a scalable production and purification method for a CVB1 260 
vaccine with thorough characterization in order to facilitate the safe development of CVB1 vaccines.  261 
To avoid animal derived contamination of the vaccine, serum free production medium was used for 262 
cell cultivation. Additionally, Vero cells were chosen for virus propagation due to their previous 263 
acceptance by regulatory authorities for human vaccine production [29]. Previously, poliovirus and 264 
EV71 were shown to grow well in Vero cells [34,36], whereas CAV6 and CAV10 grew poorly [37]. In 265 
12 
 
our study, CVB1 grew consistently well in Vero cells but modified Vero cell lines may further increase 266 
yields as described [38]. 267 
We restricted the demand on virus seed by applying a low MOI strategy with longer incubation times 268 
for virus propagation. During long virus cultivation periods, virus production was amplified with final 269 
virus yields comparable to those with short cultivation times and higher MOIs. Similar low MOI 270 
strategies have been described in the efficient propagation of EV71 [36,39] and poliovirus [34]. 271 
Stability of CVB1 in different buffers was examined to establish whether variation exists in conditions 272 
such as low salt and acidic pH (required for chromatographic purification methods); to compare to 273 
the R-buffer previously used in purifications [24]; and using buffers suitable for use in murine and 274 
human vaccines. These results were encouraging, as CVB1 was stable for one week in all buffers 275 
tested although the buffer containing low salt and low pH (pH 5), had the most significant particle 276 
size shift. Accordingly, we identify PBS or M199 media (pH 7.4) containing 0.1% Tween80 as the 277 
preferred buffers for CVB1 formulation, due to the Tween80 induced increase in virus yield and 278 
stability. This most likely occurs due to Tween80 forming complexes with CVB1 particles which 279 
increase recovery from the production medium by protecting the virus from unspecific binding to cell 280 
debris and plastic surfaces during purification. Of the two, M199 is the most preferable as it is already 281 
used in poliovirus vaccine [40] and accepted for human use, plus it contains a number of potentially 282 
virus stabilizing components. 283 
Another important feature of vaccine development is an easily standardized purification method, 284 
which is suitable for scaling-up. The gold standard for enterovirus purification is based on PEG 285 
precipitation followed by sucrose gradient ultracentrifugation and final concentrating by further 286 
ultracentrifugation. According to the literature [24,37] and our own results, this procedure leads to 287 
very pure virus but extremely low yields (Figure 2E). As such, we wanted to develop a purification 288 
protocol enabling high purity and improved yield. We introduced four alternative purification 289 
strategies based on namely, tandem sucrose cushion pelleting; tandem sucrose cushion pelleting 290 
with added Tween detergent in all purification steps; a two-step protocol relying on PEG precipitation 291 
and sucrose cushion pelleting (with Tween80); and finally a three-step protocol based on PEG 292 
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precipitation followed by gelatin chromatography and 30/50% sucrose cushion pelleting (with 293 
Tween80). 294 
The tandem pelleting approach had higher virus yields compared to the three-step protocol, and 295 
significantly, the conventional “gold standard” gradient purification. The resulting yield was 83 times 296 
higher compared to the gradient purified virus (Figure 2E), however, the purity (66%) was not as 297 
good as in three-step protocol (99%). In addition, the tandem pelleting protocol is labor demanding 298 
particularly in laboratories lacking large-scale centrifuges. In comparison, while quicker to perform, 299 
the PEG precipitation protocol (CVB1#3b) resulted in a loss of virus (15% recovery). Nevertheless, 300 
PEG precipitation improved virus purity, and the three-step protocol yielded 19 times more virus than 301 
the traditional gradient purification method, with equal purity. Since the developed protocols provide 302 
good (tandem pelleting) or high (three step protocol) purity and improved yields over standard 303 
gradient purification protocol, their selection can be determined based on the needs of each 304 
laboratory and equipment available. Our protocols offer a quicker streamlined method to produce 305 
new enterovirus vaccines for preclinical testing in animal models. 306 
Interestingly, formalin inactivation used in inactivated poliovirus vaccines caused a dramatic change 307 
in virus integrity. Following inactivation, only 5% virus protein was left in the vaccine preparation and 308 
most virus particles dispersed into smaller units, as seen with TEM (Figure 4D). This underlines the 309 
importance of properly analyzing vaccine preparations. It also indicates the poliovirus based 310 
inactivation protocol may not be suitable for other enteroviruses and virus-specific protocols may be 311 
required [36]. However, regardless of the concentration decrease, formalin-inactivated CVB1 still 312 
induced a strong virus-neutralizing antibody response in mice and protected against CVB1 infection 313 
in vivo. 314 
Future work must develop more efficient concentration and purification methods suitable for an 315 
industrial scale, based, for example, on tangential flow filtration and chromatography [34]. To 316 
produce sufficient vaccine for future studies, optimization of the CVB1 inactivation step is also 317 
necessary. 318 
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5. Conclusion 319 
 320 
In conclusion, we present an efficient and scalable CVB1 production protocol and purification 321 
process that is suitable for vaccine production. A three-step purification procedure can be scaled-up 322 
to purify several liters of virus-containing supernatant and allows for rapid progress to animal 323 
vaccination studies. For maximal virus yield an alternative tandem cushion pelleting protocol was 324 
also developed. The non-adjuvanted formalin inactivated CVB1 vaccine induced a strong, virus-325 
neutralizing antibody response in vaccinated mice, providing valuable information for the 326 
development of new enterovirus vaccines for human use. 327 
 328 
Figure legends 329 
 330 
Fig. 1. Schematic showing production and purification protocols used.  331 
Five different protocols were compared for purification of CVB1 (CVB1#1-4) and the most efficient 332 
protocol (three-step protocol) was tested also for CVB6. 333 
 334 
Fig. 2. Characterization of CVB1 and CVB6 purified with different methods.  335 
(A) Analysis of CVB1 total protein content (5 µl/well) on SDS-PAGE gel (B) and by Western blotting 336 
(1 µl/well) of VP1, stained with 5-D8/1. (C) Analysis of CVB6 total protein content on SDS-PAGE gel 337 
followed by (D) Western blotting analysis for the purified virus using pAb 1685 recognizing VP1. (E) 338 
Virus yield comparison (concentration and infectivity titer) expressed as normalized yield compared 339 
with the virus yield from CVB1#1. (F) Dynamic light scattering (DLS) analysis of CVB1#1-#4, CVB6 340 
and PBS-0.1% Tween80 buffer without virus. The boxed-in area represents the virus peaks for CVB1 341 
and CVB6. PBS-0.1% Tween80 contained 100% particles (determined by particle volume) with a 342 
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hydrodynamic diameter 10.7 nm representing Tween80 micelles. (G) The average sizes and volume 343 
distributions of the virus particles. 344 
 345 
Fig. 3. The stability profiles of different CVB1 batches stored at 4°C for one week analyzed by 346 
dynamic light scattering (DLS).  347 
The average sizes of the most predominant particles in the population were calculated from DLS 348 
measurements. (A) Purified CVB1 virus in R-buffer contained 85.0% and 91.2% particles 349 
(determined by particle volume) with a hydrodynamic diameter of 37.5 nm and 34.4 nm at days 0 350 
and 7 respectively. (B) Purified CVB1 virus in citrate buffer contained 81.7% and 98.1% particles 351 
with a hydrodynamic diameter of 32.9 nm and 52.6 nm at days 0 and 7 respectively. (C) Purified 352 
CVB1 virus in PBS-Tween buffer contained 100% and 100% particles with a hydrodynamic diameter 353 
of 46.6 nm and 54.7 nm at days 0 and 7 respectively. (D) Purified CVB1 virus in M199-Tween buffer 354 
contained 99.5% and 100.0% particles (determined by particle volume) with a hydrodynamic 355 
diameter of 41.6 nm and 40.0 nm at days 0 and 7 respectively. 356 
 357 
Fig. 4. Characterization of the CVB1#2 virus before and after formalin inactivation.  358 
(A) DLS analysis of CVB1#2 before and after formalin inactivation. (B) SDS-PAGE and WB analysis 359 
of CVB1#2 before and after inactivation. (C) TEM analysis of CVB1#2 before formalin inactivation 360 
(bar: 500 nm from 15000 x magnification, bar: 50 nm from 30000 x magnification). (D) TEM analysis 361 
of CVB1#2 after formalin inactivation (bar: 500 nm from 20000 x magnification, bar: 50 nm from 362 
30000 x magnification). 363 
 364 
Fig. 5. Mice vaccinated with CVB1 vaccine are protected against CVB1 infection.  365 
(A) Weights of mice after vaccination with 1 µg or 10 µg CVB1 vaccine. Black arrows indicate the 366 
days of vaccination. (B) Neutralizing antibody titres in mice vaccinated with 1 µg (n=4) or 10 µg (n=3) 367 
16 
 
of CVB1 vaccine ***p<0.001 compared to day 0 or as indicated (One-way ANOVA). (C) Weights of 368 
mice after infection with 106 PFU/mouse CVB1 in mice treated with 1 µg of vaccine, 10 µg of vaccine 369 
or control mice. (D) Viraemia on day 3 post infection or (E) replicating virus in the pancreas on day 370 
5 post infection in control (n=4) or vaccinated mice receiving low (1 µg, n=4) or high (10 µg, n=3) 371 
CVB1 vaccine, as measured by standard plaque assay *p<0.05 compared to both low and high 372 
vaccine doses (One-way ANOVA). (F) VP1 positivity, as detected by immunohistochemistry in the 373 
pancreas of control mice or vaccinated mice on day 5 post infection (representative images) 16X 374 
magnification on the left and 40X magnification on the right. 375 
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Tables 496 
 497 
Table 1. Neutralizing antibody titers analyzed by plaque neutralization assay. 498 
Vaccination group Neutralizing titer 
CVB1 vaccine Day 0 Day 21 Day 35 Day 42 Day 49 
Mouse 1 - 64 1024 1024 1024 
Mouse 2 16 64 2048 2048 2048 
Negative control 
  
  
Mouse 3 - 4 - - - 
Mouse 4 - - 4 - - 
 499 
Fig. 1. Schematic showing production and purification protocols used. Five different protocols were compared for purification of CVB1 (CVB1#1–4) and the most 
efficient protocol (three-step protocol) was tested also for CVB6.
Fig. 2. Characterization of CVB1 and CVB6 purified with different methods. (A) Analysis of CVB1 total protein content (5 ml/well) on SDS-PAGE gel (B) and by 
Western blotting (1 ml/well) of VP1, stained with 5-D8/1. (C) Analysis of CVB6 total protein content on SDS-PAGE gel followed by (D) Western blotting analysis for 
the purified virus using pAb 1685 recognizing VP1. (E) Virus yield comparison (concentration and infectivity titer) expressed as normalized yield compared with the 
virus yield from CVB1#1. (F) Dynamic light scattering (DLS) analysis of CVB1#1-#4, CVB6 and PBS-0.1% Tween80 buffer without virus. The boxed-in area represents 
the virus peaks for CVB1 and CVB6. PBS-0.1% Tween80 contained 100% particles (determined by particle volume) with a hydrodynamic diameter 10.7 nm 
representing Tween80 micelles. (G) The average sizes and volume distributions of the virus particles.
Fig. 3. The stability profiles of different CVB1 batches stored at 4 C for one week analyzed by dynamic light scattering (DLS). The average sizes of the 
most predominant particles in the population were calculated from DLS measurements. (A) Purified CVB1 virus in R-buffer contained 85.0% and 
91.2% particles (determined by particle volume) with a hydrodynamic diameter of 37.5 nm and 34.4 nm at days 0 and 7 respectively. (B) Purified 
CVB1 virus in citrate buffer contained 81.7% and 98.1% particles with a hydrodynamic diameter of 32.9 nm and 52.6 nm at days 0 and 7 respectively. 
(C) Purified CVB1 virus in PBS-Tween buffer contained 100% and 100% particles with a hydrodynamic diameter of 46.6 nm and 54.7 nm at days 0 
and 7 respectively. (D) Purified CVB1 virus in M199-Tween buffer contained 99.5% and 100.0% particles (determined by particle volume) with a 
hydrodynamic diameter of 41.6 nm and 40.0 nm at days 0 and 7 respectively.
Fig. 4. Characterization of the CVB1#2 virus before and after formalin inactivation. (A) DLS analysis of CVB1#2 before and after 
formalin inactivation. (B) SDS-PAGE and WB analysis of CVB1#2 before and after inactivation. (C) TEM analysis of CVB1#2 before 
formalin inactivation (bar: 500 nm from 15,000 magnification, bar: 50 nm from 30,000 magnification). (D) TEM analysis of CVB1#2 
after formalin inactivation (bar: 500 nm from 20,000 magnification, bar: 50 nm from 30,000 magnification).
Fig. 5. Mice vaccinated with CVB1 vaccine are protected against CVB1 infection. (A) Weights of mice after vaccination with 1 mg or 10 mg CVB1 vaccine. 
Black arrows indicate the days of vaccination. (B) Weights of mice after infection with 106 PFU/mouse CVB1 after treatment with 1 mg or 10 mg of 
vaccine or vaccine buffer alone. (C) Neutralizing antibody titres in mice vaccinated with 1 mg (n = 4) or 10 mg (n = 3) of CVB1 vaccine ***p < 0.001 
compared to day 0 or as indicated (One-way ANOVA). (D) Viraemia on day 3 post infection or (E) replicating virus in the pancreas on day 5 post infection 
in control (n = 4) or vaccinated mice receiving low (1 mg, n = 4) or high (10 mg, n = 3) CVB1 vaccine, as measured by standard plaque assay * p < 0.05 
compared to both low and high vaccine doses (One-way ANOVA). (F) VP1 positivity, as detected by immunohistochemistry in the pancreas of control 
mice or vaccinated mice on day 5 post infection (representative images) 16 magnification on the left and 40 magnification on the right.
SUPPLEMENTARY MATERIAL 
 
Supplementary Table 1. Details of CVB1 and CVB6 culturing and harvesting conditions. 
 
Virus Batch MOI Infection (days) Production medium 
Additives at 
harvest (vol/vol%) Virus release Virus collection Clarification 
CVB1#1 
5 2 DMEM 
0.1% Tween80 
3 x freeze-
thaw 
9610 x g, 4°C, 
20 min 
0.45 µm and 
0.2 µm vacuum 
filtration 
CVB1#2 0.3%  DOC
1,  
0.6% NP-402 
CVB1#3a 
0.01 7 Megavir 0.1% Tween80 CVB1#3b CVB1#4 
CVB6#1 0.5 
 
1Sodium Deoxycholate (DOC) 
2Nonidet(N)P-40 
 
 
 
 
 
 
 
 
 
 
 Supplementary Table 2. Details of CVB1 and CVB6 purification protocols. 
 
Virus 
Batch 
Concentration or 
purification step Solubilization Purification step Purification step Solubilization 
CVB1#1 PEG 60001 PBS-0.1% Tween80 
Discontinuous 5-20% sucrose 
gradient in PBS-0.1% Tween80, 
ultracentrifugation (103.9 k g, 4 h at 
4°C) 
Virus containing fractions were 
pooled and concentrated by 
pelleting using 
ultracentrifugation (108.6 k g, 4 
h 4°C) 
PBS-0.1% 
Tween 80 
CVB1#2 Pelleting through 30% 
sucrose cushion using 
ultracentrifugation (175 
k g, 14 h at 4°C) 
R-buffer2 Pelleting through discontinuous 
30/50% sucrose cushion by  
ultracentrifugation (285 k g, 14 h at 
4°C) 
- 
R-buffer2 
CVB1#3a 
PBS-0.1% 
Tween80 
M199-0.1% 
Tween80 
 
CVB1#3b 
PEG 60001 
 
CVB1#4 Incubation with gelatin sepharose (GE 
Healthcare #17-0956-01) rotation at 
4°C for 16 h, followed by passing the 
collected supernatant through gelatin 
sepharose column 
Pelleting through discontinuous 
30/50% sucrose cushion by 
ultracentrifugation (285 k g, 14 h 
at 4°C) 
CVB6#1 
 
1Polyethylene Glycol (PEG) 6000 
2 R-buffer composition (10 mM Tris, 200 mM NaCl, 50 mM MgCl2) 
Suplementary Figure 1. The effect of MOI and culture time for CVB1 production. 
In order to optimize the virus cultivation process in Vero-cells, the effect of MOI and culture 
time was studied by infecting them in 6-well plates with MOIs: 0.1, 0.01, 0.001, 0.0001 and 
0.00001.  The CVB1 productions were compared at days 3 – 7. The lowest yield was 
achieved with MOI 0.00001 at day 3 and the highest yield with MOI 0.001 at day 4.  
 
 
 
Supplementary Table 3. The Vero cell residual DNA quantity of the purified viruses. 
Virus batch DNA (ng/µl) 
CVB1#1 0.54 ± 0.36 
CVB1#2 0.0068 ± 0.0030 
CVB1#3a 0.146 ± 0.088 
CVB1#3b 0.259 ± 0.164 
CVB1#4 0.0005 ± 0.0004 
CVB6#1 0.034 ± 0.025 
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